Lupin on Wednesday received preliminary approval from the US FDA to market a generic equivalent of GlaxoSmithKline Plc‘s ViiV Healthcare‘s (ViiV) antiretroviral (ARV) Lexiva tablets in 700 milligram dosage form. This product was filed from the company's Goa plant which has run into a problem with the US FDA
first published: Jul 28, 2016 11:33 am
A collection of the most-viewed Moneycontrol videos.
This Tenant says Andheri West is better than SOBO | The tenant
Nifty Clocks Second Week Of Gains But Still Awaits New Peak;Midcaps Snap 7-Week Run|Closing Bell
Will Nifty Bulls March Towards Fresh Peak Despite Dismal Global Cues? | Opening Bell Live
Nifty Aims For Next 26,100 After Hitting 3-Week High |Opening Bell Live
